KALA BIO scraps development of eye disease drug after trial failure

About this update from Kalyani Investment Co. Ltd.

KALA BIO NASDAQ:KALA said on Monday it will stop developing its experimental treatment for a type of eye disease after it failed to meet the main goal in a mid-stage study.

View stock analysis, news, and events for Kalyani Investment Co. Ltd.